Wyeth is moving forward with its new drug to combat osteoporosis in post-menopausal women. The FDA has issued a second "approvable letter" for bazedoxifene. The pharmeceutical company must answer additional questions on incidence of stroke and blood clots and provide more documents to the agency before approval. The drug is a SERM (selective estrogen receptor modulator), in that it functions in a similar manner to current drug raloxifene (sold under brand name Evista), providing the patient's bones the benefits comparable to estrogen without as many risks to other body parts.
Read more about this at http://www.reuters.com/article/health-SP/idUSN2429276420071226
Published On: January 05, 2007